Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 22, 14:00-17:00
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
Stay tuned
Meeting time: Wednesday, July 22, 2026, from 14:00 to 17:00 (sign-in from 13:30 to 14:00)
14:00-14:15 Opening Remarks
14:15-15:00 Roundtable Discussion:Investment & Capital Market amid Chinese Pharma’s Global Expansion
(1)2026 Observations on Life Sciences Investment and Financing Landscape
(2)Overseas Expansion & Listing Options: Latest Regulatory Updates on Hong Kong Listings, US IPOs, Spin-off Listings and Red-chip Structures
(3)Key Legal Issues in Cross-border Transactions: Risk Control from Term Sheet to Closing
15:00-15:45 Roundtable Discussion:Core Legal Framework & Practical Highlights of Outbound Pipeline Transactions
(1)2026 Transaction Overview: Structuring & Driving Logic of License Out, NewCo, Co-Co, Platform Cooperation and Asset Acquisition
(3)Key Negotiation Points for License Out: Scope of Rights, Milestone Structuring, Diligent Obligations and Termination Provisions
(3)MNCs’ Acquisition of China-Based Assets: Deal Structure, Regulatory Barriers and Practical Solutions
(4)Patent Protection & Dispute Resolution: IP Risks and Dispute Prevention Mechanisms in Outbound Transactions (Overview)
15:45-16:00 Break
16:00-17:00 Roundtable Discussion:Frontier Compliance Topics for Chinese Pharma’s Global Expansion
(1)Cross-border Data & Human Genetic Resources (HGR) Compliance: Hidden Barriers for Outbound Transactions
(2)Latest Developments in Antitrust and Foreign Investment Screening
(3)Sanctions & Technology Export Controls: Two-Way Compliance Pressures for Outbound Chinese Pharma
17:30 Cocktail Reception
The Primus Hotel Shanghai Hongqiao is adjacent to the National Exhibition and Convention Center (Shanghai) and is within walking distance.